OnKure Therapeutics, Inc. OKUR
2.63 USD -0.38 (-12.62%)
Regular-session close
2.63 0.00 0.00%
After hours · Nov 13, 4:00 PM ET
2.60 Day range 3.08
2.01 52-week range 5.38
- YTD
- -9.31%
- 1 year
- -16.24%
- Market cap
- 108.33M
- EPS (ttm)
- -2.26
- Shares out
- 12.65M
- Forward P/E
- -2.64
- YTD return
- -9.31%
- 1-year return
- -16.24%
- Volume
- 891.35K
- Avg volume
- 324.10K
- Open
- 3.03
- Previous close
- 3.01
- Day's range
- 2.60 – 3.08
- 52-week range
- 2.01 – 5.38
- Analysts
- Strong Buy
- Price target
- 34.75 (+1221.3%)
5D +0.67 (+28.63%)
Key statistics
- Enterprise value
- 240.68M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 7.96M
- Total debt
- 6.51M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 15.50
- 200-day average
- 15.91
Fundamental scorecard
4 of 25 checks passed on OKUR’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
OKUR Revenue — quarterly 0
OKUR Net income — quarterly -17.85M
OKUR EPS — quarterly -0.36
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.97 | -1.10 | -0.13 | -13.40% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | Leerink Partners | init | — | Outperform |
| Nov 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 10, 2024 | Oppenheimer | init | — | Outperform |
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- onkuretherapeutics.com
News
Your note
Sign in to keep a note on OKUR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARRUTHERS R MICHAEL | Director | Stock Award(Grant) | Oct 3, 2024 | 4,939 |
| GREY MICHAEL G. | Officer and Director | Stock Gift | Jul 25, 2023 | 628,846 |
| HALL ASHLEY | Officer | Conversion of Exercise of derivative security | Aug 27, 2023 | 39,600 |
| LEONARD BRADEN MICHAEL | Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 24, 2024 | 0 |
| LEVERONE JASON A. CPA | Chief Financial Officer | Stock Award(Grant) | Oct 3, 2024 | 16,331 |
| NOVO HOLDINGS A/S | Beneficial Owner of more than 10% of a Class of Security | Sale | Jun 22, 2023 | 3,330,340 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| NEA Management Company, LLC | 3.78% | 478,549 | 3.91M | Sep 29, 2024 |
| BML Capital Management, LLC | 2.73% | 345,740 | 2.83M | Sep 29, 2024 |
| Highbridge Capital Management, LLC. | 2.42% | 306,269 | 2.51M | Sep 29, 2024 |
| Tang Capital Management, LLC | 2.33% | 294,626 | 2.41M | Sep 29, 2024 |
| Carlyle Group Inc. | 2.13% | 269,896 | 2.21M | Sep 29, 2024 |
| Rivervest Venture Management LLC | 2.00% | 253,422 | 2.07M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Biotechnology ETF | 0.51% | 64,795 | 530.02K | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 0.47% | 59,611 | 487.62K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.22% | 27,854 | 227.84K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.08% | 10,536 | 86.18K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.04% | 4,614 | 37.74K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.03% | 3,599 | 29.44K | Oct 30, 2024 |
